Nature Communications (Nov 2021)

Correlation of SARS-CoV-2-breakthrough infections to time-from-vaccine

  • Barak Mizrahi,
  • Roni Lotan,
  • Nir Kalkstein,
  • Asaf Peretz,
  • Galit Perez,
  • Amir Ben-Tov,
  • Gabriel Chodick,
  • Sivan Gazit,
  • Tal Patalon

DOI
https://doi.org/10.1038/s41467-021-26672-3
Journal volume & issue
Vol. 12, no. 1
pp. 1 – 5

Abstract

Read online

The duration of effectiveness of SARS-CoV-2 vaccination is not yet known. Here, the authors present preliminary evidence of BNT162b2 vaccine waning across all age groups above 16, with a higher incidence of infection in people who received their second dose early in 2021 compared to later in the year.